ArticleClinical interventions in aging2025
Serum Expression of PDCD4 and ADAM10 in Elderly Patients with Atherosclerotic Acute Myocardial Infarction and Their Combined Predictive Value for Poor Prognosis.
Article in Clinical interventions in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Programmed cell death protein 4 (PDCD4): a pleiotropic regulator in cardiovascular diseases.Journal of physiology and biochemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate serum programmed cell death factor 4 (PDCD4) and a disintegrin and metalloproteinase 10 (ADAM10) expression in elderly patients with atherosclerotic acute myocardial infarction (AMI) and assess their prognostic value. Methods: A retrospective analysis was conducted on 134 elderly patients with atherosclerotic AMI (disease group) and 110 healthy controls. Serum PDCD4 and ADAM10 levels were measured using ELISA. Based on prognosis, patients were divided into good prognosis (n=79) and poor prognosis groups (n=55). Clinical factors and biomarker levels were compared between groups. Logistic regression identified independent predictors of poor prognosis, and receiver operating characteristic (ROC) curves assessed predictive performance. Results: Serum PDCD4 and ADAM10 levels were significantly higher in AMI patients compared with controls, and further elevated in the poor prognosis group (P<0.05). Poor prognosis was also associated with older age, diabetes, STEMI, larger infarct size, anterior wall infarction, higher Killip class and GRACE score, elevated NT-proBNP and hs-CRP, and reduced LVEF (P<0.05). Logistic regression confirmed elevated PDCD4 and ADAM10, diabetes, Killip class ≥II, GRACE score ≥140, STEMI, anterior infarction, NT-proBNP increase, and reduced LVEF as independent predictors of poor prognosis (P<0.05). ROC analysis showed AUCs of 0.837 for PDCD4, 0.859 for ADAM10, and 0.931 for their combination, with the combined model outperforming either marker alone (P<0.05). Conclusion: Serum PDCD4 and ADAM10 are elevated in elderly atherosclerotic AMI patients and independently associated with poor prognosis. Combined detection may provide improved prognostic assessment, although further studies are warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.